Key Highlights
- Crinetics Pharmaceuticals surged 100% following Vertex Pharmaceuticals’ $10 billion all-cash acquisition agreement
- Rivian Automotive declined 9% after revealing plans for a 75 million share offering to repay federal loans
- Micron Technology slid 5% amid concerns about potential memory chip oversupply from South Korean manufacturers
- Fiserv climbed as much as 8% on news of potential STAR Network sale negotiations with major banking institutions
- Semiconductor and AI-related equities experienced broad declines, with Intel losing 4.4% and Samsung dropping nearly 7%
Semiconductor and artificial intelligence stocks experienced significant pressure during Tuesday’s premarket session on July 7, signaling a swift reversal from the previous day’s gains.
The downturn began overseas with Samsung Electronics. Despite projecting substantial profit growth, the South Korean technology giant saw its shares plunge nearly 7% as investors reacted negatively to the announcement.
This bearish sentiment quickly crossed into American markets. Intel Corporation tumbled 4.4%, while Micron Technology shed 5.8% ahead of the opening bell.
Other technology heavyweights including Advanced Micro Devices, Corning, Marvell Technology, and Super Micro Computer also traded lower. Each company maintains significant exposure to the artificial intelligence industry.
Nasdaq-100 futures retreated while Dow Jones futures showed relative resilience. Market participants appeared to be reassessing artificial intelligence sector valuations in anticipation of key economic releases scheduled for later this week.
Crinetics Skyrockets on Vertex Acquisition Agreement
Crinetics Pharmaceuticals emerged as the session’s standout performer. The biotech company’s shares rocketed 100%, climbing to $83.66 during premarket hours.
Vertex Pharmaceuticals unveiled plans to acquire Crinetics at $85 per share through an all-cash transaction. The deal values Crinetics’ total equity at approximately $10 billion.
The transaction is anticipated to finalize during the third quarter of 2026. Vertex emphasized that the acquisition would provide immediate revenue contributions through Palsonify, a therapy for acromegaly patients.
Vertex also highlighted atumelnant, a pipeline candidate, as a potential blockbuster opportunity worth billions. The company projects the combined product portfolio will deliver more than $5 billion in peak annual sales.
Fiserv experienced notable gains as well, advancing between 6% and 8%. Reports from The Wall Street Journal indicated that JPMorgan Chase, Bank of America, Wells Fargo, and PNC Financial Services engaged in discussions to acquire Fiserv’s STAR Network payment processing division.
Rivian Declines on Equity Offering, Micron Pressured by Oversupply Worries
Rivian Automotive ranked among the session’s weakest performers. The electric vehicle manufacturer’s shares tumbled approximately 9% following disclosure of a 75 million Class A share offering.
The company plans to use the capital raised for general corporate needs, including repayment of a $4.5 billion loan facility from the U.S. Department of Energy.
Despite the decline, Rivian delivered better-than-anticipated second-quarter revenue guidance. Management projected $1.55 billion to $1.65 billion in quarterly revenue, surpassing the $1.44 billion Wall Street consensus estimate.
Micron Technology dropped roughly 5%. Market concerns centered on the possibility that aggressive capital expenditure programs by Samsung and SK Hynix could trigger a memory chip oversupply situation, potentially compressing prices industry-wide.
SpaceX edged down 1.3% in early trading. The aerospace company was scheduled to be added to the Nasdaq 100 index prior to Tuesday’s opening bell.
Equity index futures displayed mixed signals overall. The day’s price action reflected investor uncertainty as they balanced positive pharmaceutical sector developments against mounting pressure in semiconductor and electric vehicle segments.





